1-2 of 2
Philip Beer, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4099.
https://doi.org/10.1182/blood-2019-130401
Published: 2019
Journal Articles

Growth Factor-Dependent Activation of a MYC-Induced Latent AML Program in Human Hematopoietic Cells

Elizabeth Bulaeva, Davide Pellacani, PhD, Naoto Nakamichi, MD PhD, Philip Beer, MD PhD, Colin Hammond, Alireza Lorzadeh, Michelle Moksa, Annaick Carles, Misha Bilenky, Sylvain Lefort, PhD, Jeremy Shu, Brian T. Wilhelm, PhDBSc, Andrew P. Weng, MD PhD, Martin Hirst, PhD, Connie J. Eaves, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2533.
https://doi.org/10.1182/blood-2019-122768
Published: 2019